aTyr Pharma, Inc. ATYR · Stock Open aTyr Pharma, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
aTyr Pharma, Inc. Analysis (ATYR)
Is aTyr Pharma, Inc. a good investment? aTyr Pharma, Inc. (ATYR) is currently trading at 6.18 USD. Market analysts have a consensus price target of 114.29 USD. This suggests a potential upside from current levels.
Earnings Schedule: aTyr Pharma, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -18.74.
Investor FAQ
Does aTyr Pharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is aTyr Pharma, Inc.?
aTyr Pharma, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -24.80.
Company Profile
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
| Split Date | Split Ratio to 1 |
|---|---|
| July 1, 2019 | 1:14 |
| Oct. 29, 2026 | 1:40 |
Community Discussion